Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Engin Demirdizen
Observed name:
Demirdizen, Engin
Institutions:
University of Southern Denmark,
Universitätsmedizin Göttingen
Observed institutions:
University of Southern Denmark,
Heidelberg University,
University Hospital Heidelberg,
National Center for Tumor Diseases,
Universitätsmedizin Göttingen,
DKFZ-ZMBH Alliance
show all 6
ORCID:
0009-0004-9346-7458
Observed ORCID:
0009-0004-9346-7458
OpenAlex ID:
A5078734767
Pan-cancer drivers of metastasis
2025
·
Ryan Lusby
, Engin Demirdizen
, et al.
·
Molecular Cancer
·
41
PDF
TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing
2022
·
Engin Demirdizen
, Ruslan Al-Ali
, et al.
·
Neuro-Oncology
·
38
PDF
MEOX2 homeobox gene promotes growth of malignant gliomas
2022
·
Anna Schönrock
, Elisa Heinzelmann
, et al.
·
Neuro-Oncology
·
33
PDF
CIC reduces xCT/SLC7A11 expression and glutamate release in glioma
2023
·
Jong-Whi Park
, Omer Kilic
, et al.
·
Acta Neuropathologica Communications
·
25
KRASG 12 C ‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
2024
·
Constanza Tapia Contreras
, Jonas Dominik Falke
, et al.
·
Molecular Oncology
·
22
PDF
Nuclei Isolation from Fresh Frozen Brain Tumors for Single-Nucleus RNA-seq and ATAC-seq
2020
·
Ashwin Narayanan
, Enrique Blanco-Carmona
, et al.
·
Journal of Visualized Experiments
·
20
PDF
Localization of Drosophila CENP-A to non-centromeric sites depends on the NuRD complex
2019
·
Engin Demirdizen
, Matthias Spiller-Becker
, et al.
·
Nucleic Acids Research
·
11
Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
·
Cancer Research Communications
·
2
Uncovering pan-cancer signatures of chemoresistance
2026
·
Mohammed Inayatullah
, Engin Demirdizen
, et al.
·
Genome Medicine
Figure S1 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure 4 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure S5 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure 6 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure 5 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure 2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure S2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure S3 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure 1 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Data from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Table S1 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure S4 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Table S2 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure 3 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Figure S6 from Targeting PRMT5 Inhibitor–Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam
2026
·
Valentina Spielmann
, Jonas Buchloh
, et al.
Clinical utility of solid tumor epigenetics
2021
·
Engin Demirdizen
, Julian Taranda
, et al.
·
Elsevier eBooks
Show more works
View as search
Works count:
40
Citation count:
192
H-index:
7
I10-index:
7
Year
Topic
Type